

OSTEOPOROSIS IN THE COVID-19 PANDEMIC

Osteoporosis Is a Health Crisis in the US^{1,2}



The Importance of Osteoporosis Care Through the COVID-19 Pandemic




*Data represent a population-based study of 4,140 postmenopausal women aged 50–90 years. [†]Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), including women aged ≥ 55 years from United States of America, Canada, Australia, and seven European countries. Women completed questionnaires including fracture data at baseline and years 1, 2 and 3. [‡]Retrospective, descriptive analysis of usage of the FRAX™ website using Google Analytics comparing percentage change from February to April 2020.





A joint statement by a coalition of experts representing ASBMR, AACE, ENDO, ECTS, and NOF issued guidance to assist HCPs in the management of osteoporosis that continued treatment during the COVID-19 pandemic is recommended^{17,18}

Osteoporosis Management During the COVID-19 Pandemic



How Amgen Is Supporting the Needs of the Community During the COVID-19 Pandemic

Amgen and the Amgen Foundation commit up to \$12.5 million to support COVID-19 Relief Efforts²⁹

Continue to serve the community by working with online learning partners, Khan Academy and LabXchange[™], to offer *free online learning for students*²⁹



For more information about Amgen's response to COVID-19, visit: amgen.com/covid-19

AACE = American Association of Clinical Endocrinology; ASBMR = American Society for Bone and Mineral Research; COVID-19 = Coronavirus Disease 2019; DXA = dual energy x-ray absorptiometry; ECTS = European Calcified Tissue Society; ENDO = Endocrine Society; HCP = healthcare provider; NOF = National Osteoporosis Foundation; US = United States FRAX™ is a trademark owned by the International Osteoporosis Foundation.

FRAX™ is a trademark owned by the International Osteoporosis Foundation. **References:** 1. American Society for Bone and Mineral Research. Call to action to address the crisis in the treatment of osteoporosis. https://www.asbmr.org/advocacy/sfp-initiative. Accessed January 5, 2021. 2. Lewiecki EM, et al. Osteoporos Int. 2020; 31:1299-1304. 3. International Osteoporosis Foundation. Facts & Statistics. https://www.osteoporosis.foundation/facts-statistics. Accessed November 25, 2020. 4. Johnell O, et al. Osteoporos Int. 2020; 17:1726-1733. 5. US Department of Health and Disteoporosis. Foundation. Facts & Statistics. https://www.osteoporosis.foundation/facts-statistics. Accessed November 25, 2020. 0. 4. Johnell O, et al. Osteoporos Int. 2020; 63:1999-102. 7. Costa AG, et al. *PLoS One*. 2013; 8:e3306. 8. Moreland A, et al. *MMWR Morb Mortal Wky Rep.* 2020; 69:1198-1203. 9. McCloskey EV, et al. Osteoporos Int. 2020:1-8. doi: 10.1007/s00198-020-005942-6. Epub ahead of print. 10. Conley RB, et al. *J Bone Miner Res.* 2020; 35:36-52. 11. Upadhyaya GK, et al. *J Orthop.* 2020; 69:1198-1203. 9. McCloskey EV, et al. Osteoporos Int. 2020; 13. Napoli N, et al. Nat Rev Endocrinol. 2020; 16:467-468. 14. Earp BE, et al. Orthopedics. 2020; 43:228-323. 15. American Physical Therapy Association. Impact of COVID-19 on the Physical Therapy Profession. https://www.endocrine.org. Accessed Docember 9, 2020. 19. Camachor PM, et al. *Datoer Pract.* 2020; 35: 1622. 11. Tarantino U, et al. *Int J Environ Res Public Health*. 2020; 17:7732. 22. National Osteoporosis Foundation. General Facts. www.not.org/preventingfractures/general-facts/. Accessed November 25, 2020. 23. Pal R, et al. *Othoperone* 19, 2020. 19. Camachor PM, et al. *Consult Pharm.* 2011; 32:93-98. 28. Siris ES, et al. Osteoporos Int. 2020; 35: 1022. 21. Tarantino U, et al. *Int J Environ Res Public Health*. 2020; 17:7732. 22. National Osteoporosis Foundation. General Facts. www.not.org/preventingfractures/general-facts/. Accessed November 25, 2020. 23. Pal R, et al

